Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydra-Lyte is a veterinary oral rehydration therapy (ORT) product developed and manufactured by LLOYD, Inc. (Lloyd Pharma). It is specifically formulated to provide a source of energy and essential electrolytes to animals suffering from dehydration and electrolyte depletion, conditions frequently associated with neonatal diarrhea (scours) or environmental stress. The formulation contains a balanced mixture of dextrose, sodium chloride, sodium bicarbonate, potassium chloride, and glycine. The inclusion of dextrose and glycine facilitates the active co-transport of sodium and water across the intestinal epithelium via the sodium-glucose cotransporter 1 (SGLT1) and sodium-amino acid cotransport systems, significantly enhancing rehydration efficiency. The bicarbonate component serves as a buffer to correct metabolic acidosis, while potassium and chloride replace lost intracellular and extracellular ions. It is primarily indicated for use in calves, foals, and pigs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hydra-Lyte.